# Manchester University NHS Foundation Trust: Phase 4 study completed, 657 enrolled (Liver Cirrhosis, Hepatocellular Carcinoma)

**Score:** 40/100

| Field | Value |
|---|---|
| Sponsor | Manchester University NHS Foundation Trust |
| Sponsor type | Non-US government |
| Study | Real-world Elecsys® GAAD Implementation and Validation to Improve Surveillance and Early Detection of HCC |
| NCT ID | NCT05971108 |
| Phase | Phase 4 |
| Status | completed |
| Conditions | Liver Cirrhosis; Hepatocellular Carcinoma |
| Intervention types | diagnostic test |
| Target enrollment | 657 |
| Site countries | United Kingdom |
| Posted | 2023-08-02 |
| Planned start | 2024-01-08 |
| Event | Completed |
| Event date | 2026-09-23 |
| Last update posted | 2026-10-09 |

## Why this score
- Completed: closeout, analysis and the next study ahead.
- 657 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05971108). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.